Glimepiride belongs to the sulfonylurea hypoglycemic drugs, can stimulate the pancreatic β-cells to secrete insulin to lower glucose, so as to play a therapeutic effect of the treatment of type 2 diabetes mellitus. Glimepiride is a sulfonylurea hypoglycemic drug, which is a pro-insulin secretion drug. The main mechanism of its hypoglycemic effect is to stimulate the pancreatic β-cells to secrete insulin to achieve the purpose of lowering blood sugar. The drug is generally applicable to type 2 diabetes, because type 1 diabetes is the absolute insufficiency of insulin secretion, so it is forbidden to use glimepiride this kind of hypoglycemic drug. There is a risk of hypoglycemia, so the drug needs to be applied with caution. It is recommended that diabetic patients need to consult an endocrinologist for treatment under the guidance of a doctor.